The excess in 2 5 mm follicles seen at ovarian ultrasonography is tightly associated to the follicular arrest of the polycystic ovary syndrome
|
|
- Noah Montgomery
- 5 years ago
- Views:
Transcription
1 Human Reproduction Vol.22, No.6 pp , 2007 Advance Access publication on April 20, 2007 doi: /humrep/dem060 The excess in 2 5 mm follicles seen at ovarian ultrasonography is tightly associated to the follicular arrest of the polycystic ovary syndrome Didier Dewailly 1,4, Sophie Catteau-Jonard 1, Anne-Céline Reyss 1, Catherine Maunoury- Lefebvre 1, Edouard Poncelet 2 and Pascal Pigny 3 1 Department of Endocrine Gynaecology and Reproductive Medicine, Hôpital Jeanne de Flandre, C.H.R.U., Lille, France; 2 Department of Radiology, Hôpital Jeanne de Flandre, C.H.R.U., Lille, France; 3 Laboratory of Endocrinology, Parc Eurasanté, C.H.R.U., Lille, France 4 Correspondence address. Tel: ; Fax: ; ddewailly@chru-lille.fr BACKGROUND: We previously hypothesized that the excess of 2 5 mm follicles seen at ovarian ultrasonography might be involved in the follicular arrest (FA) of polycystic ovary syndrome (PCOS), independently from the main putative contributors of FA, namely hyperandrogenism and hyperinsulinism. METHODS: A multivariate statistical analysis was applied retrospectively to clinical, biological and ultrasound data that were consecutively collected during 5 years in 457 patients with polycystic ovaries and in 188 age-matched non-hyperandrogenic and regularly cycling controls without PCO at ultrasound. RESULTS: Stepwise discriminant analysis indicated that in PCOS the 2 5 mm follicle number (FN) gave the strongest correlation to severity of the FA, followed by age and then by fasting insulin level. The other variables [waist circumference (WC), 6 9 mm FN, serum testosterone, FSH, LH and ovarian area] were rejected by the analysis. Multiple linear regression indicated a significant and independent negative relationship between the 2 5 and 6 9 mm FN in the PCOS (r , P < 0.01) and control groups (r , P<0.01). In PCOS only, the 6 9 mm FN was negatively and independently related to the WC (r , P<0.05). CONCLUSIONS: The size of the 2 5 mm follicle pool is an independent and important contributor to the FA of PCOS. This result could be explained by an exaggerated physiological inhibitory effect from this pool on the terminal follicle growth. The metabolic derangement of PCOS that also contributes to the FA would act through a different mechanism. Keywords: androgens; anovulation; follicular arrest; insulin; polycystic ovary syndrome Introduction Polycystic ovary syndrome (PCOS) is the main cause of anovulatory infertility in women (Franks, 2003). Oligo-anovulation (OA) results from ovarian follicle abnormalities that are thought to be 2-fold (Dewailly et al., 2003; Jonard and Dewailly, 2004). First, in all patients, early follicular growth is excessive, up to the step of follicles becoming sensitive to FSH (i.e. 2 5 mm in diameter). Secondly, the selection of one follicle from the increased pool of selectable follicles (i.e. 6 9 mm in diameter) and its further maturation to a dominant follicle under LH influence does not occur. This second abnormality in the folliculogenesis is named the follicular arrest (FA) and explains the ovulatory disorder of PCOS. Although the FA has not received yet a clear and unanimous explanation, hyperinsulinism (HI) and/or insulin resistance (IR) are considered as important, but not exclusive, contributors to this abnormality (Franks et al., 1998). Furthermore, FA does not always occur in patients with PCOS since some of them do ovulate monthly (Franks et al., 1998; Carmina and Lobo, 2001). In contrast, the excess of small follicles appears as the salient and constant feature of PCO. Pathological studies have shown that the pool of growing primary and secondary follicles is 2 3-fold that of normal ovaries while the pool of primordial follicle is normal (Hughesdon, 1982; Webber et al., 2003). With regard to the important intra-ovarian effects of androgens on the small follicle growth (Vendola et al., 1998; Weil et al., 1998), the hyperandrogenism (HA) of PCOS is designated as the main culprit for this follicle excess (Jonard and Dewailly, 2004). However, evidence for this is mainly experimental, based on animal studies (Vendola et al., 1998; Weil et al., 1998). Little clinical data documenting such a phenomenon is available in women with PCOS. Nevertheless, in a previous study using a selective follicular counting by ultrasound 1562 # The Author Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please journals.permissions@oxfordjournals.org
2 Follicle excess and follicular arrest in PCOS (i.e. counting separately the 2 5 and 6 9 mm follicles), we reported that the 2 5 mm follicle number (FN) was positively correlated to the serum testosterone and androstenedione levels in patients with PCOS, all three parameters being in excess in comparison to controls (Jonard et al., 2003a). In contrast, we also showed in this previous study that the proportion of larger (6 9 mm) antral follicles, relative to the 2 5 mm FN, was much less than in control women. Further, in a subsequent preliminary study (Jonard et al., 2003b), we observed a negative and significant correlation between the two follicle ranges. This may reflect an impaired transition from the 2 5 to 6 9 mm follicle stage and suggests that the excess of 2 5 mm follicles in PCOS could exert an inhibitory effect on further follicular growth. This study was designed to revisit this preliminary data and to analyse whether the contribution of the excess of 2 5 mm follicles to the FA of PCOS was direct, or indirect through other known contributors of follicular derangement in PCOS, such as HA and/or HI (Franks et al., 1998). Patients and Methods This study was approved by the Institutional Review Board of the University Hospital of Lille. All patients and controls gave an informed consent before their inclusion in this study. Data were obtained from a database including clinical, hormonal and ultrasound features that were consecutively recorded between 2000 and 2005 in patients referred to our department for HA and/or OA, as previously reported (Dewailly et al., 2006). Patient population Controls The control population consisted of 188 women who were referred to our department for IVF because of tubal and/or male infertility. Exclusion criteria were a history of menstrual disturbances (i.e. cycle length either,25 days or.35 days), hirsutism, abnormal serum level of prolactin or androgens (i.e. serum testosterone above 0.7 ng/ml), PCO at ultrasonography and hormonal treatment during the 3 months before the study. Patients with PCOS Four hundred and fifty-seven women were selected for this study. The diagnosis of PCOS was based on the association of at least two of the three following criteria according to the Rotterdam classification (The Rotterdam ESHRE/ASRMsponsored PCOS Consensus Workshop Group, 2004): (i) ovulatory disturbances, mainly oligomenorrhoea or amenorrhoea; (ii) HA as defined either clinically by hirsutism (modified Ferriman and Gallwey score.8) or severe acne/seborrhoea, and biologically by a testosterone serum level.0.7 ng/ml and (iii) more than 12 follicles in the 2 9 mm range in each ovary at ultrasonography and/or an ovarian volume higher than 10 ml. Amenorrhoea, oligomenorrhoea or regular cycles were defined as no menses during.3 months,,8 menses in the preceding year or cycle length between 25 and 35 days, respectively. Investigation procedures Blood sampling was performed in the early follicular phase, between 8.00 and 9.00 AM, between day 2 and day 7 after the last menstrual period both in PCOS patients and in controls. In PCOS patients, the last menstrual period was either spontaneous or induced by the administration of didrogesterone (10 mg/day for 7 days). Ultrasound examination was performed with a 7-MHz transvaginal transducer (Logic 400 General Electric, Milwaukee, WI, USA), the same day as blood sampling. Ultrasound measurements were taken in real time, according to a standardized protocol allowing counting separately the 2 5 and 6 9 mm follicles, as previously described (Jonard et al., 2003a). The ovarian area was measured by outlining the ovarian picture on a longitudinal plane, as previously described (Jonard et al., 2003a). Any patient with at least one follicle with a diameter greater than 9 mm or a serum estradiol level above 80 pg/ml was excluded from the study. Hormone immunoassays LH and FSH were measured using chemiluminescent two sites immunoassays on a multi-parameter system (Axsym, Abbott Laboratories, Rungis, France), while testosterone was measured in duplicate using a radioimmunoassay (Coat-a-count, total testosterone kit) provided by Diagnostic Products Corporation (La Garenne Colombes, France). Fasting serum insulin levels were measured in duplicate by an immunoradiometric assay (Bi-Insulin IRMA Pasteur, Bio-Rad, Marnes la Coquette, France) that uses two monoclonal anti-insulin antibodies. Intra- and inter-assay coefficients of variation for the insulin assay were,3.8 and 7.5%, respectively as previously described (Pigny et al., 2003). Results are expressed as miu/l in terms of the World Health Organization 66/304 reference insulin preparation. Statistical methods Comparisons between two independent groups were performed using the non-parametric Mann Whitney test. One-factor analysis of variance (ANOVA) was used for comparisons between PCOS subgroups with post hoc Bonferroni s correction for 2 2 comparisons between each group. A stepwise discriminant analysis was applied to the set of variables that differed significantly by ANOVA between PCOS subgroups. Significant and independent relationships between variables were evaluated by multiple linear regression with partial correlations allowing to control for confounding effect from any variable on the others. All statistical analyses were performed using the Statistical Package for the Social Sciences 11.5 (SPSS Inc., Chicago, IL, USA). A P-value of,0.05 was considered significant. Results The menstrual status was used as an index of the severity of the FA. Therefore, the whole PCOS group was split into three subgroups according to the menstrual status, i.e. amenorrhoea, oligomenorrhoea or regular cycles, each including 63 (13.8%), 284 (62.1%) and 110 (24%) patients, respectively. 1563
3 Dewailly et al. Table 1 shows the median values with 5th 95th percentiles of the main clinical, hormonal and ultrasound parameters in controls and each PCOS subgroup. By the Mann Whitney test, the rank of values from every PCOS subgroup differed significantly from controls for all parameters, except for age in the regular cycle subgroup (P ¼ 0.054) and for the 6 9 mm FN in the amenorrhoeic subgroup (P ¼ 0.063). One-factor ANOVA displayed significant variations between PCOS subgroups for all variables except body mass index (P ¼ 0.063). The results of the 2 2 comparisons of PCOS subgroups after post hoc analysis with Bonferroni s correction are indicated in Table 1. Interestingly, the 2 5 and 6 9 mm FNs varied inversely according to the menstrual status (Fig. 1). After stepwise discriminant analysis, the 2 5 mm FN displayed the strongest association to the menstrual status (step 1: F to eliminate ¼ 12.63), followed by age (step 2: F to eliminate ¼ 6.31) and then by insulin (step 3: F to eliminate ¼ 5.33; F minimum to include ¼ 3.84). The other variables [waist circumference (WC), testosterone, FSH, LH and ovarian area] were rejected by the analysis. When the data were reanalysed by selecting the PCOS patients with a testosterone level. 0.5 ng/ml (n ¼ 139), the discriminant analysis selected only the 2 5 mm FN and rejected all the other variables. Multiple linear regression was performed in an attempt to explain the relationship between FA and the 2 5 mm FN. A significant and independent negative relationship was found between the 2 5 mm and 6 9 mm FN in the whole PCOS group (r ¼ , P, 0.01) (Fig. 2). The 2 5 mm FN was also negatively related to age and positively related to testosterone, independently from the other variables (r ¼ , P, 0.05 and r ¼ 0.154, P, 0.01, respectively). The 6 9 mm FN was negatively related to WC, independently from the 2 5 mm FN (r ¼ , P, 0.05). A similar significant and independent negative relationship between the 2 5 and 6 9 mm FN was found in controls (r ¼ , P, 0.01) (Fig. 2). In this group, the 2 5 mm FN was also significantly and negatively related to age independently from the other variables (r ¼ , P, 0.01). Discussion Multivariate analysis in our patients with PCOS showed that the 2 5 mm FN was associated very strongly with the severity of the menstrual disorder that we used as a marker of the FA. In our stepwise discriminant analysis, this relationship was the strongest (step 1) and it was independent from two other major determinants of the FA, namely age and fasting insulin level, that were also kept in the model (steps 2 and 3, respectively). Therefore, our data confirm the well-known improving effect of age (Elting et al., 2003) as well as the worsening effect of HI (Franks et al., 1998) on the FA of PCOS. In addition, it shows that the excess in 2 5 mm follicles is another independent and important contributor to the FA of PCOS. Putatively explaining such an effect, we observed an independent and strong negative relationship between the 2 5 and 6 9 mm FN, confirming our preliminary report (Jonard et al., 2003b). Interestingly, this relationship was also found in controls, as shown in Fig. 2, thus suggesting the presence of a physiological negative influence from the 2 5 mm follicle pool on the terminal follicle growth at the time of selection, independently from the intra- or extra-ovarian factors known to intervene in this process. Putatively, the larger the number of 2 5 mm follicles, the lower the proportion of them growing to 6 9 mm and further follicles. In the normal situation, such a regulation at the time of follicle selection for dominance would serve to prevent multiple ovulation. In PCOS, this natural phenomenon would be overdriven and would thus impair any follicle to become dominant. Among the factors that may drive this regulation, the anti-müllerian hormone (AMH) presents itself as a good candidate since its expression is maximal in granulosa cells of this follicle class (Weenen et al., 2004), where it inhibits FSH-induced effects such as aromatase expression (Durlinger et al., 2001). In patients with PCOS, there is a marked increase in the serum AMH level (Pigny et al., 2003; Laven et al., 2004) and we have shown previously (Pigny et al., 2003) that it is tightly related to the 2 5 mm FN but not to the 6 9 mm FN. In addition, we recently reported in a smaller series of patients Table 1: Median values with 5th 95th percentiles (in parenthesis) of the tested variables in PCOS and control groups PCOS (n ¼ 457) Amenorrhea (n ¼ 63) Oligomenorrhea (n ¼ 284) Regular cycles (n ¼ 110) Controls (n ¼ 188) Age (years) 26.0 ( ) a,b 28.0 ( ) 28.0 ( ) 29.0 ( ) BMI (kg/m 2 ) 28.2 ( ) 25.2 ( ) 24.6 ( ) 22.9 ( ) WC (cm) 90.0 ( ) b 82.0 ( ) 80.0 ( ) 73.0 ( ) Testosterone (ng/ml) 0.58 ( ) a,b 0.46 ( ) c 0.38 ( ) 0.25 ( ) LH (IU/l) 6.8 ( ) 6.2 ( ) 4.9 ( ) 3.9 ( ) FSH (IU/l) 4.8 ( ) 5.2 ( ) 5.3 ( ) 5.9 ( ) Insulin (miu/l) 7.8 ( ) a,b 5.2 ( ) 4.4 ( ) 3.4 ( ) 2 5 mm FN 17.5 ( ) a,b 13.5 ( ) c 11.5 ( ) 4.5 ( ) 6 9 mm FN 1.5 (0 10.0) a,b 3.5 (0 12.0) 4.0 (0 12.2) 2.3 (0 5.5) Ovarian area (cm 2 ) 6.68 ( ) a,b 5.9 ( ) c 5.47 ( ) 3.9 ( ) a Amenorrhoea subgroup significantly different from oligomenorrhoea subgroup (ANOVA with post hoc analysis, P, 0.05). b Amenorrhoea subgroup significantly different from regular cycle subgroup (ANOVA with post hoc analysis, P, 0.05). c Oligomenorrhoea subgroup significantly different from regular cycle subgroup (ANOVA with post hoc analysis, P, 0.05); See Results for the comparisons between controls and each PCOS subgroup. 1564
4 Follicle excess and follicular arrest in PCOS that serum AMH level was closely related to the severity of the menstrual disorder, along with the 2 5 mm FN (Pigny et al., 2006). We hypothesize, therefore, that in PCO the excess of small antral follicles would create an exaggerated AMH tone within the microenvironment of the selectable follicles. This would impair the action of FSH and would thus contribute to Figure 2: Negative relationship between the 2 5 and 6 9 mm FN in controls (n ¼ 188) and in patients with PCOS (n ¼ 457). The upper and lower regression lines apply to the PCOS and control group, respectively. See the text for the values of the correlation coefficients. the aromatase inhibition that characterizes the FA of PCOS (Jakimiuk et al., 1997). However, we recognize that this assumption is based on correlation data that do not imply causality. Surprisingly, serum testosterone was not retained by the stepwise discriminant analysis as a variable contributing to the FA. This disagrees at first sight with many previous reports establishing a link between HA and OA in patients with PCOS (reviewed in Diamanti-Kandarakis et al., 2006). However, the explanation may reside in the fact that HA would contribute to FA via the 2 5 mm follicle excess that it favours (Vendola et al., 1998; Weil et al., 1998). Therefore, this variable did not contribute enough by itself in our stepwise discriminant analysis when challenged to stronger variables such as the 2 5 mm FN. In addition, we recently reported that this link is not constant since some patients with PCO are oligomenorrhoeic despite the absence of overt HA (Dewailly et al., 2006). Conversely, other patients with HA and PCO are eumenorrhoeic (Carmina and Lobo 2001). Altogether, these observations may indicate that in many situations the peripheral androgenic status poorly reflects the intra-ovarian androgen effects. However, the fact that only the 2 5 mm FN was selected after including only those PCOS patients with a testosterone level. 0.5 ng/ml strengthens our conclusion that HA influences the menstrual cycle abnormalities through its effect on the follicle excess in PCOS. In the more frankly hyperandrogenic patients, this 1565 Figure 1: Box-and-whisker plots showing the distribution of individual values for 2 5 (left) and 6 9 mm (right) FN in patients with PCOS, according to their menstrual status. Horizontal small bars represent the 5th 95th percentile range, and the boxes indicate the 25th 75th percentile range. The horizontal line in each box corresponds to the median. Open circles represents values beyond the 95th percentile. See Table 1 for comparisons between groups.
5 Dewailly et al. relationship overcomes the ones involving age or HI. Lastly, that serum LH and FSH were not retained by the analysis fits with the current opinion that the FA of PCOS is mainly driven by intra-ovarian abnormalities and that the gonadotropin derangement is secondary (Franks et al., 1998). In this study, the independent relationship between FA and insulin confirms the worsening effect of HI and/or IR on the FA of PCOS (Franks et al., 1998). This effect does not seem to act through amplification of the negative effect exerted by the excess of 2 5 mm follicles. Rather, it would be additive through different mechanisms, as suggested in this study by the inverse relationship between the 6 9 mm FN and the WC, independently from the 2 5 mm FN. Since WC is strongly associated to HI and/or IR, this finding is also in line with numerous reports about the negative effect of the metabolic component of PCOS on the ovulatory status (reviewed in Pasquali et al., 2006). Further to a quantitative effect (i.e. reduced proportion of 6 9 mm follicles), this metabolic influence may also exert a qualitative derangement of granulosa cells, as suggested by an insufficient production of inhibins at that follicle stage in PCO (Welt et al., 2005). This could explain why in our study patients were amenorrhoeic or oligomenorrhoeic despite the presence of an absolute number of 6 9 mm follicles that was normal or greater than controls, respectively. To conclude, this study shows that the size of the 2 5 mm follicle pool has a very strong and specific impact on the FA of PCOS. We propose the hypothesis of an autoinhibiting effect within the selectable follicle pool that exists in normal women but is exaggerated in PCOS. However, further research is warranted to support this hypothesis and clearly, more experimental data are needed in humans to elucidate which factor(s) is involved in this inhibition. Acknowledgements We thank Mrs Francine Becquin for her excellent technical help, Ms Sophie Delva, Céline Vandaele and Claire Vandamme for collecting the clinical data and Mrs Lydie Lombardo and Sylvie Vanoverschelde for collecting the blood samples. We thank Dr Patrick Devos, Centre d études et de Recherches en Informatique Médicale, University of Lille 2, for his help in the Statistics. References Carmina E, Lobo RA. Polycystic ovaries in hirsute women with normal menses. Am J Med 2001;111: Dewailly D, Catteau-Jonard S, Reyss AC et al. Oligo-anovulation with Polycystic Ovaries (PCO) but not overt hyperandrogenism. J Clin Endocrinol Metab 2006; Jul 18; [Epub ahead of print]. Dewailly D, Cortet-Rudelli C, Decanter C. The polycystic ovary syndrome: reproductive aspects. In: Wass JAH, Shalet SM (eds). The Oxford Textbook of Endocrinology. Oxford, UK, Oxford University Press: 2003, Diamanti-Kandarakis E, Papailiou J, Palimeri S. Hyperandrogenemia: pathophysiology and its role in ovulatory dysfunction in PCOS. Pediatr Endocrinol Rev 2006;3(Suppl. 1): Durlinger AL, Gruijters MJ, Kramer P et al. Anti-Müllerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. Endocrinology 2001;142: Elting MW, Kwee J, Korsen TJM et al. Aging women with polycystic ovary syndrome who achieve regular menstrual cycles have a smaller follicle cohort than those who continue to have irregular cycles. Fertil Steril 2003;79: Franks S. Assessment and management of anovulatory infertility in polycystic ovary syndrome. Endocrinol Metab Clin North Am 2003;32: Franks S, Mason H, White D et al. Etiology of anovulation in polycystic ovary syndrome. Steroids 1998;63: Hughesdon PE. Morphology and morphogenesis of the Stein-Leventhal ovary and of so-called hyperthecosis. Obstet Gynecol Surv 1982;37: Jakimiuk AJ, Jakowicki JA, Magoffin DA. Follicular development in polycystic ovary syndrome. Assist Reprod Rev 1997;7: Jonard S, Dewailly D. The follicular excess in polycystic ovaries due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest. Hum Reprod Update 2004;2:1 11. Jonard S, Dewailly D, Pigny P et al. What are the determinants of the antral follicle number at ovarian ultrasonography (U/S) in PCOS? ESHRE Congress, Madrid, 29 June to 3 July 2003, oral communication, # Hum Reprod 2003b;18(Suppl 1): 42. Jonard S, Robert Y, Cortet-Rudelli C et al. Ultrasound examination of polycystic ovaries: is it worth counting the follicles? Hum Reprod 2003a;18: Laven JSE, Mulders AGMGJ, Visser JA et al. AMH serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab 2004;89: Pasquali R, Gambineri A, Pagotto U. The impact of obesity on reproduction in women with polycystic ovary syndrome. BJOG 2006; Jul 7; [Epub ahead of print]. Pigny P, Jonard S, Robert Y et al. Serum anti-mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91: Pigny P, Merlen E, Robert Y et al. Elevated serum level of AMH in patients with PCOS: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab 2003;88: The Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19: Vendola KA, Zhou J, Adesanya OO et al. Androgens stimulate early stages of follicular growth in the primate ovary. J Clin Invest 1998;101: Webber LJ, Stubbs S, Stark J et al. Formation and early development of follicles in the polycystic ovary. Lancet 2003;362: Weenen C, von Bergh ARM, Cranfield M et al. Anti-Müllerian Hormone (AMH) expression pattern in the Human Ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod 2004;10: Weil SJ, Vendola K, Zhou J et al. Androgen receptor gene expression in the primate ovary: cellular localization, regulation, and functional correlations. J Clin Endocrinol Metab 1998;83: Welt CK, Taylor AE, Fox J et al. Follicular arrest in polycystic ovary syndrome is associated with deficient inhibin A and B biosynthesis. J Clin Endocrinol Metab 2005;90: Submitted on December 4, 2006; resubmitted on February 7, 2007; accepted on February 13,
DEFINING THE POLYCYSTIC ovary syndrome (PCOS)
0021-972X/06/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 91(10):3922 3927 Printed in U.S.A. Copyright 2006 by The Endocrine Society doi: 10.1210/jc.2006-1054 Oligoanovulation with Polycystic
More informationORIGINAL ARTICLE Reproductive endocrinology. Submitted on February 4, 2011; resubmitted on April 29, 2011; accepted on May 9, 2011
Human Reproduction, Vol.26, No.11 pp. 3123 3129, 2011 Advanced Access publication on September 16, 2011 doi:10.1093/humrep/der297 ORIGINAL ARTICLE Reproductive endocrinology Diagnosis of polycystic ovary
More informationThe relationship of serum anti- Mullerian hormone with polycystic ovarian morphology and polycystic ovary syndrome: a prospective cohort study
Human Reproduction, Vol.0, No.0 pp. 1 7, 2013 doi:10.1093/humrep/det015 Hum. Reprod. Advance Access published February 1, 2013 ORIGINAL ARTICLE Reproductive endocrinology The relationship of serum anti-
More informationRevisiting the ovarian volume as a diagnostic criterion for polycystic ovaries
Human Reproduction Vol.20, No.10 pp. 2893 2898, 2005 Advance Access publication July 8, 2005. doi:10.1093/humrep/dei159 Revisiting the ovarian volume as a diagnostic criterion for polycystic ovaries Sophie
More informationOriginal Investigation. 94 Endocrine Oncology and Metabolism. Jovanovska et al
Original Investigation Sensitivity and specificity of anti-mülerian hormone in the diagnosis of polycystic ovary syndrome in a macedonian population of women of reproductive age: a cross-sectional study
More informationLille II; and b Laboratory of Endocrinology, C.H.R.U. and Universite de Lille II, Lille, France
Increased anti-m ullerian hormone and decreased FSH levels in follicular fluid obtained in women with polycystic ovaries at the time of follicle puncture for in vitro fertilization Virginie Desforges-Bullet,
More informationClinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes
POLYCYSTIC OVARY SYNDROME Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes Ettore Guastella, M.D., a Rosa Alba Longo, M.D., b and Enrico Carmina, M.D. b a Department
More informationMETABOLIC RISK MARKERS IN WOMEN WITH POLYCYSTIC OVARIAN MORPHOLOGY
Vuk Vrhovac University Clinic Dugi dol 4a, HR-10000 Zagreb, Croatia Original Research Article Received: February 18, 2010 Accepted: March 3, 2010 METABOLIC RISK MARKERS IN WOMEN WITH POLYCYSTIC OVARIAN
More informationROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU)
ROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU) In 1935, Stein and Leventhal described 7 women with bilateral enlarged PCO, amenorrhea or irregular menses, infertility and masculinizing
More informationS. AMH in PCOS Research Insights beyond a Diagnostic Marker
S. AMH in PCOS Research Insights beyond a Diagnostic Marker Dr. Anushree D. Patil, MD. DGO Scientist - D National Institute for Research in Reproductive Health (Indian Council of Medical Research) (Dr.
More informationUltrasound examination of polycystic ovaries: is it worth counting the follicles?
Human Reproduction Vol.18, No.3 pp. 598±603, 2003 DOI: 10.1093/humrep/deg115 Ultrasound examination of polycystic ovaries: is it worth counting the follicles? S.Jonard 1, Y.Robert 3, C.Cortet-Rudelli 1,
More informationDifferentiation between polycystic ovary syndrome and polycystic ovarian morphology by means of an anti-müllerian hormone cutoff value
ORIGINAL ARTICLE Korean J Intern Med 2017;32:690-698 Differentiation between polycystic ovary syndrome and polycystic ovarian morphology by means of an anti-müllerian hormone cutoff value Do Kyeong Song,
More informationThe Egyptian Journal of Hospital Medicine (January 2018) Vol. 70 (8), Page
The Egyptian Journal of Hospital Medicine (January 2018) Vol. 70 (8), Page 1278-1288 Anti-Mullerian Hormone: An Indicator for the Severity of Polycystic Ovarian Syndrome Yehia Abd-Elsalam Wafa 1, Mohamed
More informationThe prevalence of polycystic ovary syndrome in Iranian women based on different diagnostic criteria
Prace oryginalne/original papers Endokrynologia Polska/Polish Journal of Endocrinology Tom/Volume 62; Numer/Number 3/2011 ISSN 0423 104X The prevalence of polycystic ovary syndrome in Iranian women based
More informationDepartment of Obstetrics and Gynecology, Benha Faculty of Medicine, Benha University, Egypt
Impact of laparoscopic ovarian drilling on anti-m ullerian hormone levels and ovarian stromal blood flow using three-dimensional power Doppler in women with anovulatory polycystic ovary syndrome Ashraf
More informationPolycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018
Polycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018 Learning Objectives At the conclusion of this lecture, learners should: 1) Know the various diagnostic
More informationGonadotrophin treatment in patients with Polycystic Ovary Syndrome
Int. J. Adv. Res. Biol. Sci. (218). 5(4): 95-99 International Journal of Advanced Research in Biological Sciences ISSN: 2348-869 www.ijarbs.com DOI: 1.22192/ijarbs Coden: IJARQG(USA) Volume 5, Issue 4-218
More informationANTI-MÜLLERIAN HORMONE (AMH) AS A USEFUL MARKER IN DIAGNOSIS OF POLYCYSTIC OVARY SYNDROME
General Endocrinology ANTI-MÜLLERIAN HORMONE (AMH) AS A USEFUL MARKER IN DIAGNOSIS OF POLYCYSTIC OVARY SYNDROME Laura Leonte 1,2, M. Coculescu 3, S. Radian 3, Simona Fica 4, Andra Caragheorgheopol 3, B.
More informationEndocrine control of female reproductive function
Medicine School of Women s & Children s Health Discipline of Obstetrics & Gynaecology Endocrine control of female reproductive function Kirsty Walters, PhD Fertility Research Centre, School of Women s
More informationOverview of Reproductive Endocrinology
Overview of Reproductive Endocrinology I have no conflicts of interest to report. Maria Yialamas, MD Female Hypothalamic--Gonadal Axis 15 4 Hormone Secretion in the Normal Menstrual Cycle LH FSH E2, Progesterone,
More informationAMH and PCOS phenotypes. Miro Šimun Alebić, Nataša Stojanović, Alain Duhamel, Dedier DewaIly
AMH and PCOS phenotypes Miro Šimun Alebić, Nataša Stojanović, Alain Duhamel, Dedier DewaIly and- Müllerian hormone (AMH) is produced by granulosa cells (GCs) of growing follicles Weenen et al., 2004; Jeppesen
More informationSenior resident 5 lll rd year P.G. student
International Journal of scientific research and management (IJSRM) Volume 4 Issue 06 Pages 4253-4261 2016 Website: www.ijsrm.in ISSN (e): 2321-3418 An Observational Cross Sectional Study Of Serum Anti-Mullerian
More information3. Metformin therapy for PCOS
1. Introduction The key clinical features of polycystic ovary syndrome (PCOS) are hyperandrogenism (hirsutism, acne, alopecia) and menstrual irregularity with associated anovulatory infertility. 1 The
More informationCan high serum anti-müllerian hormone levels predict the phenotypes of polycystic ovary syndrome (PCOS) and metabolic disturbances in PCOS patients?
ORIGINAL ARTICLE http://dx.doi.org/1.5653/cerm.213.4.3.135 pissn 2233-8233 eissn 2233-8241 Clin Exp Reprod Med 213;4(3):135-14 Can high serum anti-müllerian hormone levels predict the phenotypes of polycystic
More informationClinical and biochemical characteristics of polycystic ovary syndrome in Korean women
Human Reproduction Vol.23, No.8 pp. 1924 1931, 2008 Advance Access publication on June 24, 2008 doi:10.1093/humrep/den239 Clinical and biochemical characteristics of polycystic ovary syndrome in Korean
More informationIn Vitro Fertilization in Clomiphene-Resistant Women with Polycystic Ovary Syndrome
Original Article Effect of Laparoscopic Ovarian Drilling on Outcomes of In Vitro Fertilization in Clomiphene-Resistant Women with Polycystic Ovary Syndrome Maryam Eftekhar, M.D. 1, Razieh Deghani Firoozabadi,
More informationJMSCR Vol 05 Issue 05 Page May 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i5.14 Hyperinsulinemia in Polycystic Ovary Syndrome
More informationIntroduction. Luciano G. Nardo 1,4, Allen P. Yates 2, Stephen A. Roberts 3, Phil Pemberton 2, and Ian Laing 2
Human Reproduction, Vol.24, No.11 pp. 2917 2923, 2009 Advanced Access publication on July 18, 2009 doi:10.1093/humrep/dep225 ORIGINAL ARTICLE Reproductive endocrinology The relationships between AMH, androgens,
More informationNitasha Garg 1 Harkiran Kaur Khaira. About the Author
https://doi.org/10.1007/s13224-017-1082-4 ORIGINAL ARTICLE A Comparative Study on Quantitative Assessment of Blood Flow and Vascularization in Polycystic Ovary Syndrome Patients and Normal Women Using
More informationPolycystic ovarian syndrome: Are radiology departments contributing to the misdiagnosis?
Polycystic ovarian syndrome: Are radiology departments contributing to the misdiagnosis? Poster No.: C-1238 Congress: ECR 2010 Type: Scientific Exhibit Topic: Genitourinary Authors: G. Tony, N. V. Gurjar,
More informationMetformin reduces serum müllerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment
Metformin reduces serum müllerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment Richard Fleming, Ph.D., a Lyndal Harborne, B.Med., a David T. MacLaughlin,
More informationWHY NEW DIAGNOSTIC CRITERIA FOR DIFFERENT PCOS PHENOTYPES ARE URGENTLY NEEDED
WHY NEW DIAGNOSTIC CRITERIA FOR DIFFERENT PCOS PHENOTYPES ARE URGENTLY NEEDED Ricardo Azziz, M.D., M.P.H., M.B.A. Chief Officer of Academic Health & Hospital Affairs State University of New York (SUNY)
More informationInsulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study
Human Reproduction, Vol.0, No.0 pp. 1 9, 2011 doi:10.1093/humrep/der418 Hum. Reprod. Advance Access published December 5, 2011 ORIGINAL ARTICLE Reproductive endocrinology Insulin resistance and endocrine
More informationX/06/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 91(1):2 6 Copyright 2006 by The Endocrine Society doi: /jc.
0021-972X/06/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 91(1):2 6 Printed in U.S.A. Copyright 2006 by The Endocrine Society doi: 10.1210/jc.2005-1457 EXTENSIVE CLINICAL EXPERIENCE Relative
More informationPolycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks
Polycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks Kate D. Schoyer, M.D. May 6, 2016 Objectives To review how to make the diagnosis of Polycystic Ovarian Syndrome (PCOS)
More informationPCOS What s new in Diagnosis & Treatment?
PCOS What s new in Diagnosis & Treatment? Roy Homburg Maccabi Medical Services and Barzilai Medical Centre, Ashkelon, Israel. Antalya, October, 2009 PCOS diagnosis - 1990 NIH criteria - Hyperandrogenism
More informationCharacteristics of different phenotypes of polycystic ovary syndrome based on the Rotterdam criteria in a large-scale Chinese population
DOI: 10.1111/j.1471-0528.2009.02347.x www.bjog.org Fertility and assisted reproduction Characteristics of different phenotypes of polycystic ovary syndrome based on the Rotterdam criteria in a large-scale
More informationDetermining the insulin resistance rate in Polycystic Ovary Syndrome patients (PCOs)
Abstract: Determining the insulin resistance rate in Polycystic Ovary Syndrome patients (PCOs) Ashraf Olabi, Ghena Alqotini College of medicine, Aleppo University Hospital Obstetrics and Gynacology, Syria.
More informationPolycystic Ovarian Syndrome. Heidi Hallonquist, MD Concord Hospital Concord Obstetrics and Gynecology
Polycystic Ovarian Syndrome Heidi Hallonquist, MD Concord Hospital Concord Obstetrics and Gynecology Outline Definition Symptoms Causal factors Diagnosis Complications Treatment Why are we talking about
More informationComparison of anti-mullerian hormone and antral follicle count for assessment of ovarian reserve
Original Article Comparison of anti-mullerian hormone and antral follicle count for assessment of ovarian reserve Sonal Panchal, Chaitanya Nagori Dr. Nagori s Institute for Infertility and IVF, Ellisbridge,
More informationClinical Profile Polycystic Ovarian Syndrome Cases
ORIGINAL RESEARCH www.ijcmr.com - 100 Cases Himabindu Sangabathula 1, Neelima Varaganti 1 ABSTRACT Introduction: Polycystic ovary syndrome (PCOS) is most common endocrine disorders of reproductive age
More informationclinical outcome and hormone profiles before and after laparoscopic electroincision of the ovaries in women with polycystic ovary syndrome
& clinical outcome and hormone profiles before and after laparoscopic electroincision of the ovaries in women with polycystic ovary syndrome Zulfo Godinjak¹*, Ranka Javorić² 1 Gynecology and Obstetrics
More informationPolycystic Ovarian Syndrome: Is It Time to Rename PCOS to HA-PODS?
DOI 10.1007/s13224-016-0851-9 INVITED MINI REVIEW Polycystic Ovarian Syndrome: Is It Time to Rename PCOS to HA-PODS? Suvarna Satish Khadilkar 1 Received: 6 November 2015 / Accepted: 25 January 2016 / Published
More informationPolycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks. Kate D. Schoyer, M.D. May 6, 2016
Polycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks Kate D. Schoyer, M.D. May 6, 2016 Objectives To review how to make the diagnosis of Polycystic Ovarian Syndrome (PCOS)
More informationDr Stella Milsom. Endocrinologist Fertility Associates Auckland. 12:30-12:40 When Puberty is PCO
Dr Stella Milsom Endocrinologist Fertility Associates Auckland 12:30-12:40 When Puberty is PCO Puberty or Polycystic Ovary Syndrome? Stella Milsom Endocrinologist Auckland DHB, University of Auckland,
More informationThe role of AMH in anovulation associated with PCOS: a hypothesis
Human Reproduction, Vol.29, No.6 pp. 1117 1121, 2014 Advanced Access publication on April 25, 2014 doi:10.1093/humrep/deu076 OPINION The role of AMH in anovulation associated with PCOS: a hypothesis Roy
More informationPrevalence of polycystic ovarian syndrome in the Buraimi region of Oman
Original Article Brunei Int Med J. 2012; 8 (5): 248-252 Prevalence of polycystic ovarian syndrome in the Buraimi region of Oman Usha VARGHESE 1 and Shaji VARUGHESE 2, 1 Department of Internal Medicine
More informationlbt lab tests t Conrolled Ovarian Hyperstimulation Dr Soheila Ansaripour
lbt lab tests t and Conrolled Ovarian Hyperstimulation Dr Soheila Ansaripour Research Instituteof Avicenna 4/23/2012 Why good prediction of poor response good prediction i of OHSS application appropriate
More informationAntim ullerian hormone and polycystic ovary syndrome
Antim ullerian hormone and polycystic ovary syndrome Yi-Hui Lin, M.D., a Wan-Chun Chiu, Ph.D., c Chien-Hua Wu, Ph.D., b,e Chii-Ruey Tzeng, M.D., d Chun-Sen Hsu, M.D., a and Ming-I Hsu, M.D. a a Department
More informationClinical and biochemical presentation of polycystic ovary syndrome in women between the ages of 20 and 40
Human Reproduction, Vol.26, No.12 pp. 3443 3449, 2011 Advanced Access publication on September 16, 2011 doi:10.1093/humrep/der302 ORIGINAL ARTICLE Reproductive endocrinology Clinical and biochemical presentation
More informationMetformin Therapy Decreases Hyperandrogenism and Ovarian Volume in Women with Polycystic Ovary Syndrome
IJMS Vol 36, No 2, June 2011 Original Article Metformin Therapy Decreases Hyperandrogenism and Ovarian Volume in Women with Polycystic Ovary Syndrome Marzieh Farimani Sanoee 1, Nosrat Neghab 1, Soghra
More informationInvestigation of adrenal functions in patients with idiopathic hyperandrogenemia
European Journal of Endocrinology (26) 155 37 311 ISSN 84-4643 CLINICAL STUDY Investigation of adrenal functions in patients with idiopathic hyperandrogenemia Hulusi Atmaca, Fatih Tanriverdi 1, Kursad
More informationSerum Vascular Endothelial Growth Factor in Polycystic Ovary Syndrome and its Relation to Ovarian Drilling
Available online on www.ijtpr.com International Journal of Toxicological and Pharmacological Research 2014; 6(4): 123-127 Research Article ISSN: 0975-5160 Serum Vascular Endothelial Growth Factor in Polycystic
More informationPrevalence and hormonal profile of polycystic ovary syndrome in young Kashmiri women presenting with hirsutism: A hospital based study
Original Article Prevalence and hormonal profile of polycystic ovary syndrome in young Kashmiri women presenting with hirsutism: A hospital based study Majid Jahangir, MD 1 Seema Qayoom, MD ² Peerzada
More informationPrevalence of Anovulation in Subfertile Women in Kerbala 2012, A descriptive Cross-Sectional Study
Prevalence of Anovulation in Subfertile Women in Kerbala 2012, A descriptive Cross-Sectional Study Mousa Mohsen Ali* Wasan Ghazi* HayderAamerAbboud^ *Kerbala University, College of Medicine, Gynecology
More informationREVIEW. Polycystic Ovary Syndrome (PCOS), Diagnostic Criteria, and AMH. Majid Bani Mohammad 1, Abbas Majdi Seghinsara 2 * Abstract.
DOI:10.22034/APJCP.2017.18.1.17 REVIEW Polycystic Ovary Syndrome (PCOS), Diagnostic Criteria, and AMH Majid Bani Mohammad 1, Abbas Majdi Seghinsara 2 * Abstract The polycystic ovary syndrome (PCOS) is
More informationCan Sex hormone Binding Globulin Considered as a Predictor of Response to Pharmacological Treatment in Women with Polycystic Ovary Syndrome?
www.ijpm.in www.ijpm.ir Can Sex hormone Binding Globulin Considered as a Predictor of Response to Pharmacological Treatment in Women with Polycystic Ovary Syndrome? Ferdous Mehrabian, Maryam Afghahi Department
More informationFemale androgen profiles by MS for PCOS patients. CS Ho APCCMS 2010, Hong Kong 14 January 2010
Female androgen profiles by MS for PCOS patients CS Ho APCCMS 2010, Hong Kong 14 January 2010 873 women with increased serum androgens Androgen-secreting neoplasms 0.2% Classical CAH 0.6% Non-classical
More informationRelationship between Energy Expenditure Related Factors and Oxidative Stress in Follicular Fluid
Original Article Relationship between Energy Expenditure Related Factors and Oxidative Stress in Follicular Fluid Abstract This study evaluated the impact of body mass index (BMI), total calorie intake
More informationNew PCOS guidelines: What s relevant to general practice
New PCOS guidelines: What s relevant to general practice Dr Michael Costello Fertility Specialist IVF Australia UNSW Royal Hospital for Women Sydney How do we know if something is new? Louvre Museum, Paris
More informationOriginal Research Article
Original Research Article Polycystic Ovarian Syndrome: A Hormonal and Radiological Correlation Haque Riyajul Aqbalul Nazma Begum 1, K Ashoka Reddy 2, Md. Kaleemullah 3 1 Final Year Post Graduate, 2 Senior
More informationIs polycystic ovary syndrome an exception for reproductive aging?
Human Reproduction, Vol.25, No.7 pp. 1775 1781, 2010 Advanced Access publication on April 30, 2010 doi:10.1093/humrep/deq088 ORIGINAL ARTICLE Reproductive endocrinology Is polycystic ovary syndrome an
More information'The effect of weight loss on anti-müiierian hormone levels in overweight and obese women with
The effect of weight loss on anti-müiierian hormone levels in overweight and obese women with polycystic ovary syndrome and reproductive impairment This is the author submitted original manuscript (pre-print)
More informationDiagnostic Performance of Serum Total Testosterone for Japanese Patients with Polycystic Ovary Syndrome
Endocrine Journal 2007, 54 (2), 233 238 Diagnostic Performance of Serum Total Testosterone for Japanese Patients with Polycystic Ovary Syndrome TAKESHI IWASA, TOSHIYA MATSUZAKI, MASAHIRO MINAKUCHI, NAOKO
More informationTHYROID PROFILE IN POLYCYSTIC OVARIAN SYNDROME Sudhanshu Sekhara Nanda 1, Subhalaxmi Dash 2, Ashok Behera 3, Bharati Mishra 4
THYROID PROFILE IN POLYCYSTIC OVARIAN SYNDROME Sudhanshu Sekhara Nanda 1, Subhalaxmi Dash 2, Ashok Behera 3, Bharati Mishra 4 HOW TO CITE THIS ARTICLE: Sudhanshu Sekhara Nanda, Subhalaxmi Dash, Ashok Behera,
More informationFemale Reproductive Physiology. Dr Raelia Lew CREI, FRANZCOG, PhD, MMed, MBBS Fertility Specialist, Melbourne IVF
Female Reproductive Physiology Dr Raelia Lew CREI, FRANZCOG, PhD, MMed, MBBS Fertility Specialist, Melbourne IVF REFERENCE Lew, R, Natural History of ovarian function including assessment of ovarian reserve
More informationAssessment of theca cell function prior to controlled ovarian stimulation: the predictive value of serum basal/stimulated steroid levels
Human Reproduction, Vol.25, No.1 pp. 228 234, 2010 Advanced Access publication on November 6, 2009 doi:10.1093/humrep/dep378 REVIEW Reproductive endocrinology Assessment of theca cell function prior to
More informationReproductive Health in Non Alcoolic Fatty Liver Disease (NAFLD)
Reproductive Health in Non Alcoolic Fatty Liver Disease (NAFLD) Pr Sophie Christin-Maitre Reproductive Endocrine Unit, Hôpital Saint-Antoine, AP-HP Université Pierre et Marie Curie INSERM U933 Paris, France
More informationFemale Reproductive Endocrinology
Female Reproductive Endocrinology Dr. Channa Jayasena PhD MRCP FRCPath Clinical Senior Lecturer & Consultant Endocrinologist Department of Gynaecology, Hammersmith Hospital Anovulation is a common cause
More informationPolycystic ovary syndrome
Jon Havelock, MD, FRCSC Polycystic ovary syndrome Therapy for this reproductive and metabolic disorder remains focused on managing symptoms, including infertility caused by anovulation, and reducing long-term
More informationPolycystic Ovary Syndrome (PCOS):
Polycystic Ovary Syndrome (PCOS): Current diagnosis and treatment Anatte E. Karmon, MD Disclosures- Anatte Karmon, MD No financial relationships to disclose 2 Objectives At the end of this presentation,
More informationSerum anti-mullerian hormone levels during controlled ovarian hyperstimulation in women with polycystic ovaries with and without hyperandrogenism
Human Reproduction Page 1 of 6 Hum. Reprod. Advance Access published March 31, 2005 doi:10.1093/humrep/deh873 Serum anti-mullerian hormone levels during controlled ovarian hyperstimulation in women with
More informationPolycystic Ovarian Syndrome (PCOS) LOGO
Polycystic Ovarian Syndrome (PCOS) Ma qianhong Ob/Gyn Department LOGO Contents Epidemiology and Definition Pathophysiology, Endocrinological Features Diagnostic Criteria Treatment Prognosis Introduction
More informationSerum müllerian-inhibiting substance levels in adolescent girls with normal menstrual cycles or with polycystic ovary syndrome
Serum müllerian-inhibiting substance levels in adolescent girls with normal menstrual cycles or with polycystic ovary syndrome Yong Siow, Ph.D., a Sari Kives, M.D., c Paige Hertweck, M.D., b Sally Perlman,
More informationFollicle dynamics and anovulation in polycystic ovary syndrome
Human Reproduction Update, Vol.14, No.4 pp. 367 378, 2008 Advance Access publication May 22, 2008 doi:10.1093/humupd/dmn015 Follicle dynamics and anovulation in polycystic ovary syndrome Stephen Franks
More informationEpidemiological correlates among women with Polycystic ovary syndrome in South India
ISSN: 2347-3215 Volume 2 Number 9 (September-2014) pp. 181-186 www.ijcrar.com Epidemiological correlates among women with Polycystic ovary syndrome in South India Pratik Kumar Chatterjee 1, P.Prasanna
More informationComparative Evaluation of Diagnostic Efficacy of Serum. Anti-Müllerian Hormone and Ultrasound in Polycystic Ovarian Syndrome
Ankita Kumari et al ORIGINAL ARTICLE 10.5005/jp-journals-10006-1569 Comparative Evaluation of Diagnostic Efficacy of Serum Anti-Müllerian Hormone and Ultrasound in Polycystic Ovarian Syndrome 1 Ankita
More informationPolycystic Ovary Syndrome
Polycystic Ovary Syndrome Definition: the diagnostic criteria Evidence of hyperandrogenism, biochemical &/or clinical (hirsutism, acne & male pattern baldness). Ovulatory dysfunction; amenorrhoea; oligomenorrhoea
More informationAnti-Mullerian Hormone as a Predictive Factor in Assisted Reproductive Technique of Polycystic Ovary Syndrome Patients
ORIGINAL REPORT Anti-Mullerian Hormone as a Predictive Factor in Assisted Reproductive Technique of Polycystic Ovary Syndrome Patients Ashraf Aleyasin, Marzie Aghahoseini, Sara Mokhtar, and Parvin Fallahi
More informationROLE OF METFORMIN IN POLYCYSTIC OVARIAN SYNDROME
ORIGINAL ARTICLE ROLE OF METFORMIN IN POLYCYSTIC OVARIAN SYNDROME 1 2 3 Samdana Wahab, Farnaz, Rukhsana Karim ABSTRACT Objective: To assess the role of Metformin in Polycystic ovarian syndrome (PCOS).
More informationJMSCR Vol 06 Issue 09 Page September 2018
www.jmscr.igmpublication.org Impact Factor (SJIF): 6.379 Index Copernicus Value: 79.54 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v6i9.53 Role of Anti-Mullerian Hormone
More informationPolycystic Ovary Disease: A Common Endocrine Disorder in Women
Polycystic Ovary Disease: A Common Endocrine Disorder in Women Paul Kaplan, M.D. Clinical Professor of Reproductive Endocrinology - OHSU Courtesy Senior Research Associate, Human Physiology University
More informationCorrelation of Anti-Mullerian Hormone with clinical, hormonal and ultrasonographic parameters in PCOS and normo-ovulatory women
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 16, Issue 2 Ver. VIII (February. 2017), PP 51-56 www.iosrjournals.org Correlation of Anti-Mullerian Hormone
More informationCARDIOVASCULAR EVENTS IN POLYCYSTIC OVARY SYNDROME
CARDIOVASCULAR EVENTS IN POLYCYSTIC OVARY SYNDROME Enrico Carmina Executive Director & CEO of Androgen Excess & PCOS Society Professor of Endocrinology Department of Health Sciences and Mother and Child
More informationThe Relation of Serum Anti-Mullerian Hormone with Polycystic Ovary Syndrome: Correlation with Clinical and Hormonal Parameters
The Relation of Serum Anti-Mullerian Hormone with Polycystic Ovary Syndrome: Correlation with Clinical and Hormonal Parameters Alaa Mohammed Sadiq ( M.B.Ch.B, FICOG, DGO) obstetrics and gynecology, college
More informationStudy of clinical presentation in cases of Polycystic Ovarian Syndrome in rural population
Original article: Study of clinical presentation in cases of Polycystic Ovarian Syndrome in rural population 1Dr Shalini Kanotra, 2 Dr Nikita Singh*, 3 Dr V B Bangal 1 Associate Professor, OBGY Department,
More informationAssociation between Anti-Mullerian Hormone and Ovarian Response and Pregnancy in Polycystic Ovary Syndrome Patients
http://www.ijwhr.net Open Access doi 10.15296/ijwhr.2019.08 Original Article International Journal of Women s Health and Reproduction Sciences Vol. 7, No. 1, January 2019, 49 53 ISSN 2330-4456 Association
More informationReproductive Testing: Less is More G. Wright Bates, Jr., M.D. Professor and Director Reproductive Endocrinology and Infertility Objectives
Reproductive Testing: Less is More G. Wright Bates, Jr., M.D. Professor and Director Reproductive Endocrinology and Infertility Objectives 1. Review definition of infertility and impact of age 2. Stress
More informationAnti-mullerian and androgens hormones in women with polycystic ovary syndrome undergoing IVF/ICSI
Iran J Reprod Med Vol. 11. No. 11. pp: 883-890, November 2013 Original article Anti-mullerian and androgens hormones in women with polycystic ovary syndrome undergoing IVF/ICSI Menha Swellam 1 Ph.D., Abeer
More informationCam type Femoroacetabular Impingement associated with Marker for Hyperandrogenism in Women
Cam type Femoroacetabular Impingement associated with Marker for Hyperandrogenism in Women Andrew B. Wolff, MD a Torie Plowden, MD b Alexandra Napoli, BA a Benjamin McArthur, MD a Erin F. Wolff, MD b a
More informationThomas M. Barber*, John A. H. Wass*, Mark I. McCarthy* and Stephen Franks
Clinical Endocrinology (2007) 66, 513 517 doi: 10.1111/j.1365-2265.2007.02764.x ORIGINAL ARTICLE Blackwell Publishing Ltd Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea
More informationIncreased Anti-Müllerian Hormone Serum Concentrations in Prepubertal Daughters of Women with Polycystic Ovary Syndrome
Increased Anti-Müllerian Hormone Serum Concentrations in Prepubertal Daughters of Women with Polycystic Ovary Syndrome Teresa Sir-Petermann, Ethel Codner, Manuel Maliqueo, Bárbara Echiburú, Catalina Hitschfeld,
More informationDiagnostic features of polycystic ovary syndrome
REVIEW article Diagnostic features of polycystic ovary syndrome 3 N Barday-Karbanee, MB ChB, DTM&H, BSc Hons (Reprod Biol) Berg Medicross, Newville, Johannesburg T I Siebert, MMed (O&G), FCOG M H Botha,
More informationDr. Ernesto Bosch Instituto Valenciano de Infertilidad Valencia, Spain. Declared no potential conflict of interest
Dr. Ernesto Bosch Instituto Valenciano de Infertilidad Valencia, Spain Declared no potential conflict of interest Is there a role for LH in elderly patients? Dr. Ernesto Bosch Instituto Valenciano de Infertilidad.
More informationBJMHR British Journal of Medical and Health Research Journal home page:
RESEARCH ARTICLE Br J Med Health Res. 2015; 2(11) ISSN: 2394-2967 BJMHR British Journal of Medical and Health Research Journal home page: www.bjmhr.com Comparision of Anti- Mullerian and Testosternoe Hormones
More informationPolycystic Ovary Syndrome
What is the polycystic ovary syndrome? Polycystic Ovary Syndrome The polycystic ovary syndrome (PCOS) is a clinical diagnosis characterized by the presence of two or more of the following features: irregular
More informationPCOS and Obesity DUB is better treated by OCPs
PCOS and Obesity DUB is better treated by OCPs Dr. Ritu Joshi Senior consultant Fortis escorts Hospital, Jaipur Chairperson Family welfare com. FOGSI (20092012) Vice President FOGSI 2014 Introduction One
More informationReproductive FSH. Analyte Information
Reproductive FSH Analyte Information 1 Follicle-stimulating hormone Introduction Follicle-stimulating hormone (FSH, also known as follitropin) is a glycoprotein hormone secreted by the anterior pituitary
More informationObjectives 06/21/18 STILL A PLACE FOR PILLS DON T IVF EVERYTHING. Clomiphene citrate and Letrozole. Infertility Case Studies. Unexplained Infertility
STILL A PLACE FOR PILLS DON T IVF EVERYTHING Jeff Roberts M.D. Co-Director, Pacific Centre for Reproductive Medicine Objectives 1 2 3 4 5 Clomiphene citrate and Letrozole Infertility Case Studies Unexplained
More informationAddressing Practice Gaps in PCOS
Addressing Practice Gaps in PCOS PCOS Challenge September 21, 2014 Ricardo Azziz, MD, MPH, MBA President, Georgia Regents University CEO, Georgia Regents Health System Introduction PCOS research began
More information